Tagged with Biogen

UK Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with developing Alzheimer’s products at a time when many MNCs are winding down their neurology programs. How would you describe Biogen’s…

Canada At the company’s 40th anniversary, Biogen’s Canadian head Marina Vasiliou gives an insight into her priorities as new managing director, her approach to building relationships with all stakeholders in the healthcare system to ensure access to Biogen’s innovative treatments, and explains how the portfolio of the neuroscience leader is perfectly…

Brazil Sameer Savkur, country manager of Biogen Brazil, provides insights into the key specificities of the Brazilian pharmaceutical ecosystem and documents the great successes of Biogen affiliate in working hand-in-hand with all key public and regulatory stakeholders in Brazil, as recently illustrated with Biogen’s innovative treatment for spinal muscular atrophy (SMA),…

Switzerland It is tempting to characterize Switzerland’s global pharma and life science hotspots as beginning and ending with Basel – home of industry giants Roche and Novartis. However, Zurich, Geneva, and even tiny Zug are all now staking serious claims for global recognition in this area. “Zurich is the world’s smallest…

Slovakia Biogen Slovakia’s Country Director on being an innovative global biotech in Slovakia, market access in the country, and the company’s commitment to improving the lives of patients through MS, Alzheimer’s and rare disease treatments. Ms. Strapkova Boydova, you have been Country Director of Biogen Slovakia since its inception in 2006.…

Pharma MD Natascha Schill discusses the growing importance and commitment that Biogen has to Switzerland, including a USD one billion investment in new facilities and the creation of 400 jobs in the upcoming years; investing in the local workforce to support the company’s growth. The headline-making news at the moment is…

Pharma Michaela Hrdlickova of Biogen elaborates on how it is the industry’s responsibility to educate all stakeholders within the Czech Republic in order to embed a health consciousness in every individual and discusses the unique referencing methods applied in the country and their resulting challenges for both industry and patient. When…

Pharma The President and MD of Abiogen Pharma discusses his family company’s recent milestones, the reasons for persisting with local manufacturing, and the benefits of international partnerships. You created Abiogen back in 1997, following the acquisition of Istituto Gentili by MSD, in order to maintain your family’s entrepreneurial tradition and build…

Biogenerics The founder and general manager of Biotechnova considers the potential of Colombia for biotechnological innovation, and explains the current state of the biogeneric industry in Latin America. Please start by introducing yourself, and explaining how you came to found Biotechnova. My background is in microbiology and infections: since 2003, there…

Biogen Idec Having experienced many years at big pharmaceutical companies, you moved into the biotech sector by joining Biogen Idec late 2010. What made you decide to switch? To me, it was an easy decision. It was an appealing challenge to join a company that was in growth mode but where many…

Biogen Idec Czech Republic Ms. Hrdličková, can you please begin by introducing yourself to our readers, and providing a brief overview of your pharmaceutical career? My educational background is in general and molecular biology, with a specialization in microbiology. I worked for approximately three years doing clinical work in this field at a hospital,…

Biogen Idec - China You have been here in China for about a year. What were your assumptions about China before you arrived and were things more or less what you thought they would be or were you surprised about the reality on the ground? We conducted extensive research and scouting before setting up…